New Systemic Options for Managing cSCC: A Care Team Forum

Program Overview

This is the first of a 2-part round-table discussion that brings together the expertise of a dermatologist, medical oncologist, and Mohs surgeon and pairs it with a first-hand account of how Jim, a cutaneous squamous cell carcinoma (cSCC) survivor, and his caregiver navigated the ups and downs of a rapidly-metastatic cSCC diagnosis and treatment labyrinth. In this activity, learners will explore pressing questions regarding the safety and efficacy of new systemic options for managing advanced cSCC not otherwise amenable to curative surgical strategies.

Credit Expired

Target Audience

The intended audience for this activity is Mohs surgeons, medical oncologists, and dermatologists who manage patients with cutaneous squamous cell carcinoma (cSCC).

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Utilize novel and emerging agents to manage advanced cutaneous squamous cell carcinoma (cSCC) based on their efficacy and safety data and mechanisms of action
  • Incorporate shared decision making (SDM), quality of life assessment and management, and collaborative care for patients with cSCC to improve patient outcomes

Activity Faculty

Chrysalyne D. Schmults, MD, MSCE

Chrysalyne D. Schmults, MD, MSCE

Associate Professor, Dermatology
Harvard Medical School
Director, Mohs and Dermatologic Surgery Center
Dana-Farber/Brigham and Women’s Cancer Center
Boston, MA

Omid Hamid, MD

Omid Hamid, MD

Chief, Translational Research and Immunotherapy
Director, Cutaneous Oncology
The Angeles Clinic and Research Institute
Los Angeles, CA

Anokhi Jambusaria, MD, MSCE, FAAD

Anokhi Jambusaria, MD, MSCE, FAAD

Assistant Professor, Division of Dermatology
Department of Internal Medicine
The University of Texas
Austin Dell Medical School
Austin, TX


Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources